Most Recent
A judge has put a proposal for a common fund order in a class action against sandalwood producer Quintis on hold as the court awaits judgment in an historic challenge to the power of courts to make common fund orders.
Poppy processor TPI Enterprises has agreed to stop selling seed from high codeine poppy plants while it defends a lawsuit by rival Tasmanian Alkaloids alleging TPI infringed two of its innovation patents for high codeine-concentrated poppy.
Technology solutions firm Byte Power Group has paid a $33,000 penalty for violating its continuous disclosure obligations by telling shareholders a proposed cryptocurrency exchange was "well advanced" when development yet to begin.
A former mining executive has been sentenced to 18 months in prison for buying shares in ASX-listed Minotaur Exploration based on information gleaned through a joint venture with the mining exploration company.
Biotech company Cryosite has agreed to pay $1.05 million to settle the competition regulator's landmark case alleging it jumped the gun on a proposed merger agreement with rival Cell Care.
Railway technology company Wavetrain Systems has asked the court to bar a competitor started by its former CEO from making allegedly false claims about its patented rail safety devices to clients.
Two Macquarie Private Wealth advisers have won their appeal of an order by the Australian Securities and Investments Commission that banned them for 10 years for falsifying emails and misclassifying client advice.
AFT Pharmaceuticals has launched a partial challenge to a court ruling that its Maxigesic ads made a number of misleading claims, including that the drug provides stronger and more effective relief than Reckitt Benckiser's Nuromol.
Clive Palmer is facing the music after riffing off Twisted Sister's 1980s anthem 'We're Not Gonna Take It' in his election campaign ads, with Universal Music lodging a copyright infringement case against the aspiring MP.
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.